Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.41 |
| ▸ | FASN | P49327 | 7/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.36 |
| ▸ | SCN2B | O60939 | 2/20 | 0.36 |
| ▸ | SCN1A | P35498 | 2/20 | 0.36 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801155 | 0.90 | POLB (0.40) | RBP4FASNEGLN1F11 | |
| SCHEMBL2799694 | 0.90 | TAS2R14 (0.48) | FASNTAS2R14EGLN1F11CNR2 | |
| SCHEMBL2801617 | 0.86 | FASN (0.38) | RBP4FASNEGLN1F11 | |
| SCHEMBL2800540 | 0.85 | TAS2R14 (0.43) | FASNTAS2R14EGLN1F11CNR2 | |
| SCHEMBL2802567 | 0.85 | EGLN1 (0.38) | RBP4FASNSCN9AEGLN1F11 | |
| SCHEMBL2803081 | 0.85 | FASN (0.40) | FASNSCN9ASCN2BSCN1B | |
| SCHEMBL2799916 | 0.85 | EGLN1 (0.39) | RBP4FASNSCN9AEGLN1F11 | |
| SCHEMBL2800585 | 0.83 | RBP4 (0.39) | RBP4FASNEGLN1 | |
| SCHEMBL2800621 | 0.82 | SPR (0.41) | RBP4FASNSCN9AEGLN1SCN2B | |
| SCHEMBL2802285 | 0.82 | FASN (0.35) | RBP4FASNSCN5ASCN9ASCN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | RBP4 92/4885FASN 4286/4885TAS2R14 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.